berberine has been researched along with Body Weight in 62 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All clinical trials exploring the effects of berberine supplementation on indices of obesity were included." | 9.05 | The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. ( Clark, CCT; Dorosti, M; Găman, MA; Kord-Varkaneh, H; Mousavi, SM; Niu, L; Rahmani, J; Taghizade-Bilondi, H; Talaei, S; Xiong, P; Zarezadeh, M; Zhang, J, 2020) |
| " To determine the antiobesity effects of BBR, the food consumption, body weight, fat contents, serum leptin, and glucose level were investigated." | 7.96 | Berberine for Appetite Suppressant and Prevention of Obesity. ( Jung, E; Park, HJ; Shim, I, 2020) |
| " Rhizoma coptidis (RC) and its main active compound, berberine, have either antimicrobial or anti-obesity activities." | 7.77 | Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. ( Cui, K; Gu, D; Li, J; Xie, W; Zhang, Y, 2011) |
| "A total of 184 eligible patients with NAFLD were enrolled and randomly received (i) lifestyle intervention (LSI), (ii) LSI plus pioglitazone (PGZ) 15mg qd, and (iii) LSI plus BBR 0." | 6.80 | Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. ( Chang, XX; Deng, W; Feng, R; Gao, X; Jia, WP; Jiang, JD; Liu, J; Rao, SX; Tu, YF; Wang, Y; Xia, MF; Yan, HM; Yao, XZ; Zeng, MS, 2015) |
| "Berberine (BBR), which is a compound derived from the Chinese medicinal plant Coptis chinensis, promotes weight loss, but the molecular mechanisms are not well understood." | 5.91 | Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes. ( Gong, S; Hu, F; Leng, Q; Li, C; Li, L; Li, X; Xu, Y; Yang, Y; Zhang, H, 2023) |
| "Chronic stress and depression are challenging conditions to treat, owing to their complexity and lack of clinically available and effective therapeutic agents." | 5.46 | Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. ( Liu, H; Sun, Y; Zhang, C; Zhu, X, 2017) |
| "Osteoporosis was induced by bilateral ovariectomy." | 5.46 | Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway. ( Dai, Z; Guo, MF; He, XF; Li, H; Sui, FG; Tian, GF; Zhang, CH; Zhang, L; Zhang, LF; Zhao, CR, 2017) |
| "Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity." | 5.43 | Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016) |
| "Cardiac hypertrophy is a maladaptive change in response to pressure overload, and is also an important risk for developing heart failure." | 5.40 | Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. ( Chen, SL; Iqbal, J; Li, B; Li, MH; Mao, WX; Mi, QY; Wang, ZM; Xie, HG; Yang, SH; Yu, YH; Zhang, YJ, 2014) |
| " All clinical trials exploring the effects of berberine supplementation on indices of obesity were included." | 5.05 | The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. ( Clark, CCT; Dorosti, M; Găman, MA; Kord-Varkaneh, H; Mousavi, SM; Niu, L; Rahmani, J; Taghizade-Bilondi, H; Talaei, S; Xiong, P; Zarezadeh, M; Zhang, J, 2020) |
| " Berberine, which is a modulator of TRPV1, has proven antiobesity and antidiabetic potentials." | 3.96 | Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels. ( Bansal, Y; Bishnoi, M; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, DP; Singh, R; Sodhi, RK, 2020) |
| " To determine the antiobesity effects of BBR, the food consumption, body weight, fat contents, serum leptin, and glucose level were investigated." | 3.96 | Berberine for Appetite Suppressant and Prevention of Obesity. ( Jung, E; Park, HJ; Shim, I, 2020) |
| "The present study aimed to investigate the effects of berberine (BRB) on spatial and learning memory, anxiety, acetylcholinesterase activity and cell death in an experimental model of intracerebroventricular streptozotocin (ICV-STZ) induced sporadic Alzheimer's-like dementia." | 3.83 | Berberine protects against memory impairment and anxiogenic-like behavior in rats submitted to sporadic Alzheimer's-like dementia: Involvement of acetylcholinesterase and cell death. ( Abdalla, FH; Adefegha, SA; Baldissarelli, J; da Silva Bernardi, J; de Andrade, CM; de Oliveira, JS; Dornelles, GL; Lenz, LS; Magni, LP; Palma, TV; Pillat, MM; Rubin, MA; Signor, C, 2016) |
| " Rhizoma coptidis (RC) and its main active compound, berberine, have either antimicrobial or anti-obesity activities." | 3.77 | Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. ( Cui, K; Gu, D; Li, J; Xie, W; Zhang, Y, 2011) |
| " donovani but was not as potent as meglumine antimonate (Glucantime), a standard drug for the treatment of leishmaniasis." | 3.68 | Berberine derivatives as antileishmanial drugs. ( Hanson, WL; Klayman, DL; Lovelace, JK; Vennerstrom, JL; Waits, VB, 1990) |
| "A total of 184 eligible patients with NAFLD were enrolled and randomly received (i) lifestyle intervention (LSI), (ii) LSI plus pioglitazone (PGZ) 15mg qd, and (iii) LSI plus BBR 0." | 2.80 | Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. ( Chang, XX; Deng, W; Feng, R; Gao, X; Jia, WP; Jiang, JD; Liu, J; Rao, SX; Tu, YF; Wang, Y; Xia, MF; Yan, HM; Yao, XZ; Zeng, MS, 2015) |
| "00001) in a linear The dose-response relationship (Pearson r = - 0." | 2.61 | Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis. ( Long, Y; Ni, L; Tao, J; Wu, R; Xu, J; Yu, N; Yuan, X; Zhang, Y, 2019) |
| "Berberine (BBR), which is a compound derived from the Chinese medicinal plant Coptis chinensis, promotes weight loss, but the molecular mechanisms are not well understood." | 1.91 | Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes. ( Gong, S; Hu, F; Leng, Q; Li, C; Li, L; Li, X; Xu, Y; Yang, Y; Zhang, H, 2023) |
| " Alkaloids from Coptis chinensis are the main plasma components related to the toxic effects of TAZF." | 1.72 | Toxicity and toxicokinetics of the ethanol extract of Zuojin formula. ( Gao, Y; Li, L; Li, Y; Liu, X; Shan, D; Wang, Q; Wang, S; Yang, Z; Zhang, T; Zhang, Y, 2022) |
| "Postprandial hyperglycemia is an important causative factor of type 2 diabetes mellitus, and permanent localization of intestinal GLUT2 in the brush border membrane is an important reason of postprandial hyperglycemia." | 1.62 | Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice. ( Dong, L; Li, J; Yang, E; Yang, H; Zhang, M, 2021) |
| "Berberine (BBR) is an isoquinoline alkaloid extracted from Chinese herbs and exhibits glucose lowering properties." | 1.62 | Supplemental Berberine in a High-Fat Diet Reduces Adiposity and Cardiac Dysfunction in Offspring of Mouse Dams with Gestational Diabetes Mellitus. ( Chen, L; Cole, LK; Dolinsky, VW; Hatch, GM; Sparagna, GC; Vandel, M; Xiang, B; Zhang, M, 2021) |
| "Berberine has been reported to have pharmacological activity in adipose tissue to anti-obesity, while the mechanism remains unclear." | 1.62 | Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway. ( Cao, L; He, Z; Jiang, X; Kong, J; Li, N; Ma, G; Song, X; Wang, Z; Wen, D; Xu, Y; Yang, F; Yu, T; Yu, Y; Zheng, L, 2021) |
| "Lung cancer is the worldwide leading cause of cancer-related death." | 1.51 | 8-Cetylcoptisine, a new coptisine derivative, induces mitochondria-dependent apoptosis and G0/G1 cell cycle arrest in human A549 cells. ( Han, B; Jiang, P; Li, X; Liu, L; Liu, W; Ma, W; Wu, S; Xu, H; Ye, X; Zhang, J, 2019) |
| " NAFLD model was established by high fat food, and rats were administrated with lovastatin, berberine, curcumin, berberine + curcumin at the dosage of 100, 100, 100, 50 + 50 mg/kg bw, respectively." | 1.48 | Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. ( Feng, WW; Kuang, SY; Liu, TS; Ma, ZJ; Pang, JY; Tu, C; Wang, JB; Wang, YH; Xiao, XH; Zang, QC; Zhao, YL, 2018) |
| "The rat model of hyperlipidemia was established by providing high-fat-diet (HFD) for 4 weeks." | 1.46 | Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats. ( Liu, L; Ni, H; Ren, F; Ren, J; Shen, T; Wei, H; Wei, J; Xu, S; Zhou, X, 2017) |
| "Osteoporosis was induced by bilateral ovariectomy." | 1.46 | Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway. ( Dai, Z; Guo, MF; He, XF; Li, H; Sui, FG; Tian, GF; Zhang, CH; Zhang, L; Zhang, LF; Zhao, CR, 2017) |
| "Chronic stress and depression are challenging conditions to treat, owing to their complexity and lack of clinically available and effective therapeutic agents." | 1.46 | Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. ( Liu, H; Sun, Y; Zhang, C; Zhu, X, 2017) |
| " However, the implication of these mechanisms is unclear because of the low bioavailability of BBR." | 1.46 | Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. ( Aa, J; Aa, N; Cao, B; Chen, Q; Fei, F; Feng, D; Feng, S; Ge, C; Guo, GL; Guo, J; He, J; Huang, J; Kong, B; Pan, Y; Schumacher, JD; Shen, J; Sun, R; Wang, G; Wang, P; Yang, CS; Yang, N; Yu, X, 2017) |
| "Hyperlipidemia is a major component of metabolic syndrome, and often predicts cardiovascular diseases." | 1.43 | Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds. ( Ji, G; Li, M; Shu, X; Xu, H; Yang, L; Zhang, C; Zhang, L, 2016) |
| "Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity." | 1.43 | Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016) |
| " However, pharmacokinetic studies showed that berberine was poorly absorbed into the body so the levels of berberine in the blood and target tissues were far below the effective concentrations revealed." | 1.42 | A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine. ( Aa, J; Cao, B; Gu, S; Hylemon, PB; Li, Y; Liu, L; Paletta, JL; Radlon, JM; Ridlon, JM; Sun, R; Tang, Y; Wang, G; Wu, X; Wu, XL; Zha, W; Zhao, C; Zhou, H, 2015) |
| "Berberine is known to improve glucose and lipid metabolism disorders, but it poorly absorbed into the blood stream from the gut." | 1.40 | Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine. ( Li, M; Li, W; Ping, F; Wang, Z; Xiao, X; Yu, M; Zhang, H; Zhang, Q; Zheng, J, 2014) |
| "Cardiac hypertrophy is a maladaptive change in response to pressure overload, and is also an important risk for developing heart failure." | 1.40 | Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. ( Chen, SL; Iqbal, J; Li, B; Li, MH; Mao, WX; Mi, QY; Wang, ZM; Xie, HG; Yang, SH; Yu, YH; Zhang, YJ, 2014) |
| "CCl4-induced chronic liver fibrosis model in mice was established and activated rat hepatic stellate cell was treated with BBR." | 1.40 | Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase. ( Chen, L; Guan, F; Kan, M; Li, J; Pan, Y; Wang, Y; Xiao, X; Zhang, X, 2014) |
| " In the present study, we aimed to investigate the effect of berberine combined with atorvastatin on LOX‑1 and explore the underlying molecular mechanism involved." | 1.40 | Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages. ( Chi, L; Hu, X; Pan, N; Peng, L; Zhang, Y, 2014) |
| " BBR solid lipid nanoparticles (SLNs) were prepared to achieve improved bioavailability and prolonged effect." | 1.39 | Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. ( Gao, DH; Li, XJ; Li, XM; Li, ZP; Liu, SH; Ou, ZM; Xue, M; Yang, MX; Yang, SY; Zhang, W, 2013) |
| "Doxorubicin, a very potent and often used anti-cancer drug, is largely limited due to the dose-related toxic effects." | 1.38 | Protective effects of berberine on doxorubicin-induced hepatotoxicity in mice. ( Chen, Y; Luo, Y; Tong, N; Zhang, J; Zhao, X, 2012) |
| "Treated with berberine for 4 weeks, elevated blood pressure and heightened levels of urine protein, blood urea nitrogen and serum creatinine in model rats were depressed significantly (P < 0." | 1.37 | [Effects and mechanism of berberine on the hypertensive renal injury rats induced by enriched high fat-salt-fructose diet]. ( Cai, Y; Li, HB; Lv, JH; Qi, CL, 2011) |
| "Berberine treatment significantly delayed the point of death after 20 Gy, but not 16 Gy, abdominal RT (p < ." | 1.36 | Effects of berberine against radiation-induced intestinal injury in mice. ( Chen, ZT; Hao, P; Hu, YD; Li, DZ; Li, GH; Tang, JL; Wang, DL; Wei, H; Zhang, YP, 2010) |
| "Wistar rat colon cancer model was induced by 1-2 dimethylhydrazine (DMH) (40 mg x kg(-1), sc) + 1% dextran sodium sulfate solution (DSS) (freely drinking)." | 1.36 | [Preventive effects of berberine on experimental colon cancer and relationship with cyclooxygenase-2 expression]. ( Wu, K; Yang, J; Zhou, Q, 2010) |
| " However, the facts that berberine had low bioavailability and poor absorption through the gut wall indicated that berberine might exert its antihyperglycaemic effect in the intestinal tract before absorption." | 1.35 | Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats. ( Deng, Y; Liu, L; Liu, X; Lu, S; Xie, L; Yu, S, 2008) |
| " In conclusion, berberine restores diabetic endothelial dysfunction through enhanced NO bioavailability by up-regulating eNOS expression and down-regulating expression of NADPH oxidase." | 1.35 | Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. ( Chen, L; Li, J; Liu, Y; Lv, X; Song, Y; Wang, C; Zhang, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.84) | 18.2507 |
| 2000's | 5 (8.06) | 29.6817 |
| 2010's | 44 (70.97) | 24.3611 |
| 2020's | 10 (16.13) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, M | 3 |
| Yang, H | 1 |
| Yang, E | 1 |
| Li, J | 6 |
| Dong, L | 1 |
| Wang, S | 1 |
| Zhang, T | 1 |
| Liu, X | 6 |
| Yang, Z | 1 |
| Li, L | 2 |
| Shan, D | 1 |
| Gao, Y | 1 |
| Li, Y | 3 |
| Zhang, Y | 5 |
| Wang, Q | 2 |
| Li, C | 1 |
| Leng, Q | 1 |
| Hu, F | 1 |
| Xu, Y | 4 |
| Gong, S | 1 |
| Yang, Y | 3 |
| Zhang, H | 2 |
| Li, X | 4 |
| Zhang, W | 4 |
| Xu, JH | 1 |
| Yu, T | 2 |
| Chen, QK | 1 |
| Singh, R | 1 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Singh, DP | 1 |
| Bishnoi, M | 1 |
| Kondepudi, KK | 1 |
| Medhi, B | 1 |
| Kuhad, A | 1 |
| Xiong, P | 1 |
| Niu, L | 1 |
| Talaei, S | 1 |
| Kord-Varkaneh, H | 1 |
| Clark, CCT | 1 |
| Găman, MA | 1 |
| Rahmani, J | 1 |
| Dorosti, M | 1 |
| Mousavi, SM | 1 |
| Zarezadeh, M | 1 |
| Taghizade-Bilondi, H | 1 |
| Zhang, J | 3 |
| Park, HJ | 1 |
| Jung, E | 1 |
| Shim, I | 1 |
| Cole, LK | 1 |
| Chen, L | 3 |
| Sparagna, GC | 1 |
| Vandel, M | 1 |
| Xiang, B | 1 |
| Dolinsky, VW | 1 |
| Hatch, GM | 1 |
| Di, S | 1 |
| Han, L | 1 |
| An, X | 1 |
| Kong, R | 1 |
| Gao, Z | 1 |
| Wang, X | 2 |
| Zhang, P | 1 |
| Ding, Q | 1 |
| Wu, H | 2 |
| Wang, H | 1 |
| Zhao, L | 1 |
| Tong, X | 1 |
| Ibrahim Fouad, G | 1 |
| Ahmed, KA | 1 |
| Ma, G | 1 |
| Zheng, L | 1 |
| Jiang, X | 1 |
| Yang, F | 2 |
| Wang, Z | 2 |
| Li, N | 1 |
| He, Z | 1 |
| Song, X | 1 |
| Wen, D | 1 |
| Kong, J | 1 |
| Yu, Y | 2 |
| Cao, L | 1 |
| Zhu, X | 1 |
| Sun, Y | 1 |
| Zhang, C | 2 |
| Liu, H | 1 |
| He, XF | 1 |
| Zhang, L | 6 |
| Zhang, CH | 1 |
| Zhao, CR | 1 |
| Li, H | 2 |
| Zhang, LF | 1 |
| Tian, GF | 1 |
| Guo, MF | 1 |
| Dai, Z | 1 |
| Sui, FG | 1 |
| Xiao, Y | 1 |
| Tian, C | 1 |
| Huang, T | 1 |
| Han, B | 2 |
| Wang, M | 1 |
| Ma, H | 2 |
| Li, Z | 1 |
| Ye, X | 3 |
| Zhou, X | 1 |
| Ren, F | 1 |
| Wei, H | 2 |
| Liu, L | 5 |
| Shen, T | 1 |
| Xu, S | 1 |
| Wei, J | 1 |
| Ren, J | 1 |
| Ni, H | 1 |
| Feng, WW | 1 |
| Kuang, SY | 1 |
| Tu, C | 1 |
| Ma, ZJ | 1 |
| Pang, JY | 1 |
| Wang, YH | 1 |
| Zang, QC | 1 |
| Liu, TS | 1 |
| Zhao, YL | 1 |
| Xiao, XH | 1 |
| Wang, JB | 1 |
| Xie, H | 1 |
| Zhang, X | 5 |
| Wang, T | 1 |
| Hu, W | 1 |
| Manicum, T | 1 |
| Chen, H | 1 |
| Sun, L | 1 |
| Jiang, P | 1 |
| Xu, H | 2 |
| Liu, W | 1 |
| Wu, S | 1 |
| Ma, W | 1 |
| Wu, L | 1 |
| Xia, M | 1 |
| Duan, Y | 1 |
| Jiang, H | 1 |
| Hu, X | 2 |
| Yan, H | 1 |
| Gu, Y | 1 |
| Shi, H | 1 |
| Gao, X | 2 |
| Xu, J | 1 |
| Long, Y | 1 |
| Ni, L | 1 |
| Yuan, X | 1 |
| Yu, N | 1 |
| Wu, R | 1 |
| Tao, J | 1 |
| Cicero, AF | 1 |
| Tartagni, E | 1 |
| Ertek, S | 1 |
| Moghaddam, HK | 1 |
| Baluchnejadmojarad, T | 1 |
| Roghani, M | 1 |
| Goshadrou, F | 1 |
| Ronaghi, A | 1 |
| Xue, M | 2 |
| Yang, MX | 2 |
| Li, XM | 2 |
| Gao, DH | 1 |
| Ou, ZM | 2 |
| Li, ZP | 2 |
| Liu, SH | 2 |
| Li, XJ | 2 |
| Yang, SY | 2 |
| Pan, Y | 2 |
| Kan, M | 1 |
| Xiao, X | 2 |
| Wang, Y | 2 |
| Guan, F | 1 |
| Li, MH | 1 |
| Zhang, YJ | 1 |
| Yu, YH | 1 |
| Yang, SH | 1 |
| Iqbal, J | 1 |
| Mi, QY | 1 |
| Li, B | 1 |
| Wang, ZM | 1 |
| Mao, WX | 1 |
| Xie, HG | 1 |
| Chen, SL | 1 |
| Chi, L | 1 |
| Peng, L | 1 |
| Pan, N | 1 |
| Zhang, Q | 1 |
| Li, M | 2 |
| Li, W | 1 |
| Yu, M | 1 |
| Ping, F | 1 |
| Zheng, J | 1 |
| Gu, S | 1 |
| Cao, B | 2 |
| Sun, R | 2 |
| Tang, Y | 1 |
| Paletta, JL | 1 |
| Wu, X | 1 |
| Wu, XL | 1 |
| Zha, W | 1 |
| Zhao, C | 1 |
| Ridlon, JM | 1 |
| Radlon, JM | 1 |
| Hylemon, PB | 1 |
| Zhou, H | 1 |
| Aa, J | 2 |
| Wang, G | 3 |
| Zou, ZY | 1 |
| Hu, YR | 1 |
| Wang, YZ | 1 |
| He, K | 2 |
| Xia, S | 1 |
| Xue, DF | 1 |
| Li, XG | 1 |
| Ye, XL | 1 |
| Yan, HM | 1 |
| Xia, MF | 1 |
| Chang, XX | 1 |
| Yao, XZ | 1 |
| Rao, SX | 1 |
| Zeng, MS | 1 |
| Tu, YF | 1 |
| Feng, R | 1 |
| Jia, WP | 1 |
| Liu, J | 1 |
| Deng, W | 1 |
| Jiang, JD | 1 |
| Zhou, J | 3 |
| Du, X | 1 |
| Long, M | 1 |
| Zhang, Z | 1 |
| Zhou, S | 2 |
| Qian, G | 1 |
| Cao, Y | 1 |
| Pan, Q | 1 |
| Cai, W | 1 |
| Shen, F | 1 |
| Chen, GY | 1 |
| Xu, LM | 1 |
| Fan, JG | 1 |
| Ye, L | 1 |
| Yuan, H | 1 |
| Shu, X | 1 |
| Yang, L | 1 |
| Ji, G | 1 |
| Yang, W | 1 |
| She, L | 1 |
| Yu, K | 1 |
| Yan, S | 1 |
| Tian, X | 1 |
| Ma, S | 1 |
| He, Q | 1 |
| Mei, D | 1 |
| Sha, S | 1 |
| Fan, S | 1 |
| Wang, L | 2 |
| Dong, M | 1 |
| de Oliveira, JS | 1 |
| Abdalla, FH | 1 |
| Dornelles, GL | 1 |
| Adefegha, SA | 1 |
| Palma, TV | 1 |
| Signor, C | 1 |
| da Silva Bernardi, J | 1 |
| Baldissarelli, J | 1 |
| Lenz, LS | 1 |
| Magni, LP | 1 |
| Rubin, MA | 1 |
| Pillat, MM | 1 |
| de Andrade, CM | 1 |
| Yang, N | 1 |
| Kong, B | 1 |
| Feng, D | 1 |
| Yu, X | 1 |
| Ge, C | 1 |
| Huang, J | 1 |
| Shen, J | 1 |
| Wang, P | 1 |
| Feng, S | 1 |
| Fei, F | 1 |
| Guo, J | 1 |
| He, J | 1 |
| Aa, N | 1 |
| Chen, Q | 1 |
| Schumacher, JD | 1 |
| Yang, CS | 1 |
| Guo, GL | 1 |
| Qiu, YY | 1 |
| Tang, LQ | 2 |
| Wei, W | 2 |
| Zhou, JY | 1 |
| Zhou, SW | 1 |
| Zhang, KB | 1 |
| Tang, JL | 2 |
| Guang, LX | 1 |
| Ying, Y | 2 |
| Li, DD | 1 |
| Deng, Y | 1 |
| Yu, S | 1 |
| Lu, S | 1 |
| Xie, L | 2 |
| Xu, YC | 1 |
| Guo, FJ | 1 |
| Meng, Y | 1 |
| Li, ML | 1 |
| Tang, J | 1 |
| Zhang, K | 1 |
| Guang, L | 1 |
| Huang, Y | 1 |
| Li, D | 1 |
| Wang, C | 1 |
| Lv, X | 1 |
| Song, Y | 1 |
| Liu, Y | 1 |
| Shen, YB | 1 |
| Piao, XS | 1 |
| Kim, SW | 1 |
| Liu, P | 1 |
| Li, GH | 1 |
| Zhang, YP | 1 |
| Chen, ZT | 1 |
| Hu, YD | 1 |
| Li, DZ | 1 |
| Hao, P | 1 |
| Wang, DL | 1 |
| Wu, K | 1 |
| Yang, J | 1 |
| Zhou, Q | 1 |
| Bhutada, P | 1 |
| Mundhada, Y | 1 |
| Bansod, K | 1 |
| Tawari, S | 1 |
| Patil, S | 1 |
| Dixit, P | 1 |
| Umathe, S | 1 |
| Mundhada, D | 1 |
| Dunnick, JK | 1 |
| Singh, B | 1 |
| Nyska, A | 1 |
| Peckham, J | 1 |
| Kissling, GE | 1 |
| Sanders, JM | 1 |
| Li, HB | 1 |
| Cai, Y | 1 |
| Qi, CL | 2 |
| Lv, JH | 1 |
| Xie, W | 1 |
| Gu, D | 1 |
| Cui, K | 1 |
| Tang, YH | 1 |
| Sun, ZL | 1 |
| Fan, MS | 1 |
| Li, ZX | 1 |
| Huang, CG | 1 |
| Chueh, WH | 1 |
| Lin, JY | 1 |
| Wu, D | 1 |
| Wen, W | 1 |
| Zhao, RX | 1 |
| Lü, JH | 1 |
| Zhong, CY | 1 |
| Chen, YY | 1 |
| Zhao, X | 1 |
| Tong, N | 1 |
| Chen, Y | 1 |
| Luo, Y | 1 |
| Yi, J | 1 |
| Wang, D | 1 |
| Wang, FL | 1 |
| Zhu, LN | 1 |
| Cai, M | 1 |
| Haller, J | 1 |
| Kiem, DT | 1 |
| Makara, GB | 1 |
| Miyahara, T | 1 |
| Tezuka, Y | 1 |
| Namba, T | 1 |
| Suzuki, T | 1 |
| Dowaki, R | 1 |
| Watanabe, M | 1 |
| Nemoto, N | 1 |
| Tonami, S | 1 |
| Seto, H | 1 |
| Kadota, S | 1 |
| Vennerstrom, JL | 1 |
| Lovelace, JK | 1 |
| Waits, VB | 1 |
| Hanson, WL | 1 |
| Klayman, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus[NCT00633282] | Phase 2 | 184 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572] | Phase 4 | 120 participants (Anticipated) | Interventional | 2017-08-16 | Recruiting | ||
| Assess the Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals With Obesity and Non-alcoholic Fatty Liver Disease[NCT05647915] | Phase 4 | 326 participants (Anticipated) | Interventional | 2022-12-15 | Not yet recruiting | ||
| The Study of Berberine Affecting Metabolism, Inflammation Status, Endothelial Function and Thrombotic Events in Patients With Coronary Artery Disease by Remodeling Gut Microbiota[NCT04434365] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2019-06-21 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for berberine and Body Weight
| Article | Year |
|---|---|
The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials.
Topics: Berberine; Body Mass Index; Body Weight; Dietary Supplements; Humans; Hypoglycemic Agents; Obesity; | 2020 |
Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Berberine; Berberis; Body Weight; Cricetina | 2019 |
Nutraceuticals for metabolic syndrome management: from laboratory to benchside.
Topics: Animals; Berberine; Body Weight; Cardiovascular Diseases; Cinnamomum zeylanicum; Dietary Supplements | 2014 |
2 trials available for berberine and Body Weight
| Article | Year |
|---|---|
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis | 2015 |
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis | 2015 |
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis | 2015 |
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis | 2015 |
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis | 2015 |
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis | 2015 |
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis | 2015 |
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis | 2015 |
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis | 2015 |
The effects of berberine on the magnitude of the acute inflammatory response induced by Escherichia coli lipopolysaccharide in broiler chickens.
Topics: Animals; Berberine; Blood Cell Count; Body Weight; Cell Line; Chickens; Digestion; Hybridomas; Infla | 2010 |
57 other studies available for berberine and Body Weight
| Article | Year |
|---|---|
Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cell Line; Diabetes Mellitus, Experimental; Epitheli | 2021 |
Toxicity and toxicokinetics of the ethanol extract of Zuojin formula.
Topics: Alkaloids; Animals; Berberine; Body Weight; Coptis; Drugs, Chinese Herbal; Ethanol; Female; Male; Ra | 2022 |
Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes.
Topics: Adipocytes, Brown; Adipose Tissue, Brown; Animals; Berberine; Body Weight; Growth Differentiation Fa | 2023 |
Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2019 |
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.
Topics: Animals; Antipsychotic Agents; Berberine; Body Temperature; Body Weight; Cytokines; Drinking; Female | 2020 |
Berberine for Appetite Suppressant and Prevention of Obesity.
Topics: Animals; Appetite Depressants; Berberine; Blood Glucose; Body Weight; Feeding Behavior; Leptin; Lipi | 2020 |
Supplemental Berberine in a High-Fat Diet Reduces Adiposity and Cardiac Dysfunction in Offspring of Mouse Dams with Gestational Diabetes Mellitus.
Topics: Adiposity; Animals; Berberine; Body Weight; Diabetes, Gestational; Diet, High-Fat; Dietary Supplemen | 2021 |
In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Computational Biology; Computer Simulation; Diabetes | 2021 |
The protective impact of berberine against doxorubicin-induced nephrotoxicity in rats.
Topics: Animals; Apoptosis; Berberine; Biomarkers; Body Weight; Doxorubicin; Fibrillar Collagens; Inflammati | 2021 |
Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.
Topics: Adipose Tissue, Brown; AMP-Activated Protein Kinases; Animals; Berberine; Blotting, Western; Body We | 2021 |
Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays.
Topics: Animals; Behavior, Animal; Berberine; Bifidobacterium; Body Weight; Depression; Disease Models, Anim | 2017 |
Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway.
Topics: Animals; Antioxidants; Berberine; Body Weight; Bone Density; Female; Femur; NF-kappa B; Osteoporosis | 2017 |
8-Cetylberberine inhibits growth of lung cancer in vitro and in vivo.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Berberine; Biomarkers, Tumor; Bod | 2018 |
Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats.
Topics: Administration, Oral; Animals; Apolipoprotein B-48; Berberine; Body Weight; Cholesterol, LDL; Coptis | 2017 |
Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Berberine; Biologi | 2018 |
Possible therapeutic potential of berberine in the treatment of STZ plus HFD-induced diabetic osteoporosis.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Berberine; Blood Glucose; Body Weight; Bone Density; Deoxyguan | 2018 |
8-Cetylcoptisine, a new coptisine derivative, induces mitochondria-dependent apoptosis and G0/G1 cell cycle arrest in human A549 cells.
Topics: A549 Cells; Animals; Apoptosis; Berberine; Body Weight; Caspase 3; Cell Line, Tumor; Cyclin D; Cycli | 2019 |
Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans.
Topics: Adipocytes; Adipose Tissue, Brown; Adult; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agent | 2019 |
Berberine chloride improved synaptic plasticity in STZ induced diabetic rats.
Topics: Animals; Berberine; Body Weight; Data Interpretation, Statistical; Dentate Gyrus; Diabetes Mellitus, | 2013 |
Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles.
Topics: Administration, Oral; Analysis of Variance; Animals; Berberine; Body Weight; Eating; Glucose; Hypogl | 2013 |
Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Blotting, Western; Body Weight; Cell Proliferatio | 2014 |
Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy.
Topics: Animals; Arterial Pressure; Autophagy; Berberine; Blotting, Western; Body Weight; Cardiomegaly; Card | 2014 |
Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Berberine; Body Weight; Cells, Cul | 2014 |
Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experime | 2014 |
A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine.
Topics: Administration, Oral; Animals; Berberine; Body Weight; Cholestanetriol 26-Monooxygenase; Cholesterol | 2015 |
Coptisine attenuates obesity-related inflammation through LPS/TLR-4-mediated signaling pathway in Syrian golden hamsters.
Topics: Animals; Berberine; Body Weight; Cholesterol; Cholesterol, LDL; Coptis; Diet, High-Fat; Disease Mode | 2015 |
Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Berberine; Body Weight; Carnitine O-Palm | 2015 |
Neuroprotective effect of berberine is mediated by MAPK signaling pathway in experimental diabetic neuropathy in rats.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Diabetic Neuropathies; Diet, High-Fat; Dietary Carbo | 2016 |
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal | 2016 |
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal | 2016 |
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal | 2016 |
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal | 2016 |
Protective mechanisms of berberine against experimental autoimmune myocarditis in a rat model.
Topics: Animals; Autoantibodies; Autoimmune Diseases; Berberine; Body Weight; Cytokines; Disease Models, Ani | 2016 |
Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds.
Topics: Animals; Berberine; Body Weight; Diet, High-Fat; Feces; Gastrointestinal Microbiome; Hyperlipidemias | 2016 |
Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model.
Topics: Animals; Berberine; Body Weight; Coptis; Diet, High-Fat; Hyperlipidemias; Hypolipidemic Agents; Insu | 2016 |
ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis.
Topics: Animals; Autophagy; Berberine; Body Weight; Cell Line; Diet, High-Fat; Disease Models, Animal; Extra | 2016 |
Berberine protects against memory impairment and anxiogenic-like behavior in rats submitted to sporadic Alzheimer's-like dementia: Involvement of acetylcholinesterase and cell death.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Anxiety; Berberine; B | 2016 |
Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Topics: Animals; Bacteria; Berberine; Bile Acids and Salts; Body Weight; CD36 Antigens; Diet, High-Fat; Fece | 2017 |
Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cell Proliferation; Diabetic Nephropathies; Down-Reg | 2017 |
Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Chemical and Drug Induced Liver Injury; Diabetes Mel | 2008 |
Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats.
Topics: alpha-Glucosidases; Animals; Berberine; Bile Acids and Salts; Blood Glucose; Body Weight; Data Inter | 2008 |
Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus.
Topics: Acrolein; Animals; Berberine; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Glucose Tra | 2008 |
Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats.
Topics: Animals; Berberine; Body Weight; Diabetes Mellitus, Experimental; Dietary Carbohydrates; Dietary Fat | 2009 |
Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin.
Topics: Animals; Berberine; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary | 2009 |
Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cells, Cultured; Eating; Glucagon-Like Peptide 1; Hu | 2010 |
Effects of berberine against radiation-induced intestinal injury in mice.
Topics: Amine Oxidase (Copper-Containing); Animals; Apoptosis; Berberine; Body Weight; Eating; Fatty Acid-Bi | 2010 |
[Preventive effects of berberine on experimental colon cancer and relationship with cyclooxygenase-2 expression].
Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Animals; Berberine; Body Weight; Colonic Neoplasms; Cycl | 2010 |
Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes.
Topics: Acetylcholine; Administration, Oral; Analysis of Variance; Animals; Antioxidants; Ascorbic Acid; Ber | 2011 |
Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle.
Topics: Animals; Berberine; Body Weight; Carcinogens; Female; Flavonolignans; Hydrastis; Liver Neoplasms; Ma | 2011 |
[Effects and mechanism of berberine on the hypertensive renal injury rats induced by enriched high fat-salt-fructose diet].
Topics: Animals; Berberine; Blood Pressure; Body Weight; Creatinine; Diet; Diet, High-Fat; Disease Models, A | 2011 |
Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice.
Topics: Animals; Araceae; Bacteroidetes; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Feces; Gastr | 2011 |
Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice.
Topics: Acrolein; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Cholesterol, HDL; Ch | 2012 |
Protective effect of berberine on serum glucose levels in non-obese diabetic mice.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Energy Intake; Female; Gl | 2012 |
Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cholesterol; Creatinine; Diabetes Mellitus, Experime | 2012 |
Protective effects of berberine on doxorubicin-induced hepatotoxicity in mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Berberine; Body Weight; Chemical and Dru | 2012 |
Safety evaluation of main alkaloids from Rhizoma Coptidis.
Topics: 3T3-L1 Cells; Alkaloids; Animals; Berberine; Berberine Alkaloids; Blood Proteins; Body Weight; Copti | 2013 |
Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cyclic AMP; Diabetes Mellitus, Experimental; Diabeti | 2013 |
Do alpha-2 adrenoceptors modify coping strategies in rats?
Topics: Adaptation, Psychological; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Ag | 1995 |
The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine.
Topics: Animals; Anti-Bacterial Agents; Apoptosis; Berberine; Body Weight; Bone Density; Bone Resorption; Ca | 1999 |
Berberine derivatives as antileishmanial drugs.
Topics: Animals; Antiprotozoal Agents; Berberine; Berberine Alkaloids; Body Weight; Cricetinae; Leishmaniasi | 1990 |